Cellular Therapy and Transplantation Section, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Cellular Therapy and Transplantation Section, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia.
Transplant Cell Ther. 2023 Oct;29(10):635.e1-635.e8. doi: 10.1016/j.jtct.2023.07.020. Epub 2023 Jul 28.
Revaccination after hematopoietic cell transplantation (HCT) is critical to prevent morbidity and mortality from vaccine-preventable illnesses. The global aim of our quality improvement initiative was to enhance timely, correct, and effective revaccination after pediatric HCT. The SMART aim of our project was to decrease median unvaccinated time by 4 months by decreasing the time to vaccine eligibility, time from eligibility to vaccine initiation, and time to completion of the vaccine series. A multidisciplinary group performed a cross-sectional quantitative and qualitative evaluation of revaccination practices at our institution. We identified factors associated with delayed, incorrect, or incomplete revaccination. Several plan-do-study-act interventions were implemented to address these drivers, including revising immune readiness criteria, increasing auditing of primary care administered immunizations, and, importantly, establishing a dedicated revaccination clinic within the HCT clinic at our center. The time to vaccine eligibility decreased from 12.6 months to 10 months (a 20% decrease), and the time to complete the vaccine series decreased from 19.3 months to 15.7 months (a 19% decrease). With a quality improvement initiative, we addressed the many causes of delayed or incomplete revaccination post-HCT and through a team-based approach successfully decreased the time to vaccine start and time to vaccine completion at our center.
造血细胞移植(HCT)后再接种疫苗对于预防疫苗可预防疾病的发病率和死亡率至关重要。我们质量改进计划的全球目标是加强儿科 HCT 后及时、正确和有效地进行再接种。我们项目的 SMART 目标是通过减少疫苗接种资格时间、从资格到疫苗接种开始时间以及完成疫苗系列的时间,将中位数未接种时间减少 4 个月。一个多学科小组对我们机构的再接种实践进行了横断面定量和定性评估。我们确定了与延迟、不正确或不完整再接种相关的因素。实施了几项计划-执行-研究-行动干预措施来解决这些驱动因素,包括修订免疫准备标准、增加对初级保健管理的免疫接种的审核,以及在我们中心的 HCT 诊所内建立专门的再接种诊所。疫苗接种资格时间从 12.6 个月减少到 10 个月(减少 20%),完成疫苗系列的时间从 19.3 个月减少到 15.7 个月(减少 19%)。通过质量改进计划,我们解决了 HCT 后延迟或不完全再接种的许多原因,并通过基于团队的方法成功地减少了我们中心的疫苗开始时间和疫苗完成时间。